S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

IKT Inhibikase Therapeutics Inc

1.22

-0.08 (-6.15%)

Last Updated: 11:48:59

Delayed by 15 minutes

Form D - Notice of Exempt Offering of Securities

Inhibikase Therapeutics (NASDAQ:IKT)
Historical Stock Chart
From Sep 2024 to Oct 2024

Click Here for more Inhibikase Therapeutics Charts.

Inhibikase Therapeutics (NASDAQ:IKT)
Historical Stock Chart
From Oct 2023 to Oct 2024

Click Here for more Inhibikase Therapeutics Charts.

Inhibikase Therapeutics Inc News

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
Wednesday 14 August 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 14 August 2024 (2 months ago) • Edgar (US Regulatory)

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
Wednesday 7 August 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 July 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 18 July 2024 (2 months ago) • Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933
Tuesday 18 June 2024 (3 months ago) • Edgar (US Regulatory)

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
Monday 17 June 2024 (3 months ago) • GlobeNewswire Inc.

Form PRE 14A - Other preliminary proxy statements
Monday 10 June 2024 (4 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 10 June 2024 (4 months ago) • Edgar (US Regulatory)

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
Wednesday 5 June 2024 (4 months ago) • GlobeNewswire Inc.

Form D - Notice of Exempt Offering of Securities
Tuesday 4 June 2024 (4 months ago) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Wednesday 22 May 2024 (4 months ago) • Edgar (US Regulatory)

More Inhibikase Therapeutics Inc News Articles

Branded Legacy (PK)

Revance Therapeutics

GNCC Capital (CE)

Enzolytics (PK)

Mullen Automotive

Saddle Ranch Media (PK)

CyberFuels (PK)

Clean Vision (QB)

Marketing Worldwide (PK)

Valiant Eagle (PK)

Net Savings Link (PK)

Fannie Mae (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions